Overview
What JHTV does with the nation's largest research base to turn discoveries into treatments.
Producing great science is one thing; getting it to patients is another. At Johns Hopkins, the nation's top NIH recipient, the job of closing that gap falls to Johns Hopkins Technology Ventures (JHTV), which links faculty discoveries with the companies that can turn them into treatments.
This case study traces how that works: two FDA approvals born in Hopkins labs, Pylarify and Voranigo; a decade-long partnership with Bayer; and JHTV's case for measuring success by patient impact, not just patents and licensing revenue.
The full case study is available to Cure Members. Join here.
